Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)

Caroline Hertler, Jörg Felsberg, Dorothee Gramatzki, Emilie Le Rhun, Jennifer Clarke, Riccardo Soffietti, Wolfgang Wick, Olivier Chinot, François Ducray, Patrick Roth, Kerrie McDonald, Peter Hau, Andreas F. Hottinger, Jaap Reijneveld, Oliver Schnell, Christine Marosi, Michael Glantz, Amélie Darlix, Giuseppe Lombardi, Dietmar KrexMartin Glas, David A. Reardon, Martin van den Bent, Florence Lefranc, Ulrich Herrlinger, Evangelia Razis, Antoine F. Carpentier, Samuel Phillips, Roberta Rudà, Antje Wick, Emeline Tabouret, David Meyronet, Claude Alain Maurage, Elisabeth Rushing, Robert Rapkins, Elisabeth Bumes, Monika Hegi, Astrid Weyerbrock, Dawit Aregawi, Christian Gonzalez-Gomez, Alessia Pellerino, Martin Klein, Matthias Preusser, Martin Bendszus, Vassilis Golfinopoulos, Andreas von Deimling, Thierry Gorlia, Patrick Y. Wen, Guido Reifenberger, Michael Weller

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Background: Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined. Methods: European Organization for Research and Treatment of Cancer (EORTC) 1419 (ETERNITY) is a registry study supported by the Brain Tumor Funders Collaborative in the US and the EORTC Brain Tumor Group. Patients with glioblastoma surviving at least 5 years from diagnosis were identified at 24 sites in Europe, US, and Australia. In patients with isocitrate dehydrogenase (IDH) wildtype tumours, prognostic factors were analysed using the Kaplan-Meier method and the Cox proportional hazards model. A population-based reference cohort was obtained from the Cantonal cancer registry Zurich. Results: At the database lock of July 2020, 280 patients with histologically centrally confirmed glioblastoma (189 IDH wildtype, 80 IDH mutant, 11 incompletely characterised) had been registered. In the IDH wildtype population, median age was 56 years (range 24–78 years), 96 patients (50.8%) were female, 139 patients (74.3%) had tumours with O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Median overall survival was 9.9 years (95% confidence interval [95% CI] 7.9–11.9). Patients without recurrence experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p < 0.001) and had a high rate (48.8%) of MGMT promoter-unmethylated tumours. Conclusions: Freedom from progression is a powerful predictor of overall survival in long-term survivors with glioblastoma. Patients without relapse often have MGMT promoter-unmethylated glioblastoma and may represent a distinct subtype of glioblastoma.

Original languageEnglish (US)
Article number112913
JournalEuropean Journal of Cancer
StatePublished - Aug 2023

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this